Merck cements its position as dominant developer of immunotherapy – Financial Times
Financial Times |
Merck cements its position as dominant developer of immunotherapy
Financial Times Merck cemented its position as the dominant developer of immunotherapy after a large clinical trial showed lung cancer patients taking its drug lived for longer than those on chemotherapy. Immunotherapy drugs, which work by encouraging the body's … Lung Cancer Drug From Merck Solidifies Lead in Crowded Field Cancer Drug Keytruda a New Weapon Against Advanced Lung Tumors |
